Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application

Author： Smith Kerrington D Shao Michael Y Posner Mitchell C Weichselbaum Ralph R

ISSN： 1479-6694

Source： Future Oncology, Vol.3, Iss.5, 2007-10, pp. : 545-556

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors

By Kanai Ryuichi Rabkin Samuel D

CNS Oncology, Vol. 2, Iss. 2, 2013-03 ,pp. : 129-142

Future Medicine

Access to resources Recommend Favorite

Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?

By Kanai Ryuichi Wakimoto Hiroaki Cheema Tooba Rabkin Samuel D

Future Oncology, Vol. 6, Iss. 4, 2010-04 ,pp. : 619-634

Future Medicine

Access to resources Recommend Favorite

Oncolytic herpes simplex virus treatment of metastatic breast cancer

International Journal of Oncology, Vol. 40, Iss. 3, 2012-01 ,pp. : 757-763

Spandidos Publications

Access to resources Recommend Favorite

Angiogenesis Inhibition Using an Oncolytic Herpes Simplex Virus Expressing Endostatin in a Murine Lung Cancer Model

By Goodwin Jonathan M. Schmitt Anthony D. McGinn Christopher M. Fuchs Bryan C. Kuruppu Darshini Tanabe Kenneth K. Lanuti Michael

Cancer Investigation, Vol. 30, Iss. 3, 2012-02 ,pp. : 243-250

Informa Healthcare

Access to resources Recommend Favorite

An oncolytic herpes simplex virus vector, G47∆, synergizes with paclitaxel in the treatment of breast cancer

Oncology Reports, Vol. 29, Iss. 6, 2013-01 ,pp. : 2355-2361

Spandidos Publications

Access to resources Recommend Favorite